Patent ID: 8114403
Filing Date: 2012-02-14
Classification: A61P,C07K,G01N

Abstract:
1. A method of treating a human afflicted with a cancer comprising cancer cells expressing human CD200 protein, the method comprising: administering to the human a therapeutic composition comprising an anti-CD200 antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment being present in an amount sufficient to promote production of one or more Th1 cytokines in the human to thereby treat the cancer, wherein the anti-CD200 antibody or antigen-binding fragment thereof binds to human CD200 protein expressed on the cancer cells and wherein the anti-CD200 antibody or antigen-binding fragment thereof inhibits the interaction between human CD200 and the human CD200 receptor, wherein the anti-CD200 antibody or antigen-binding fragment thereof comprises: (A): (i) a light chain polypeptide comprising: a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO: 209; a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO: 209; and a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO: 209; and (ii) a heavy chain polypeptide comprising: a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 195; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 174; and a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 149; or (B): (i) a light chain polypeptide having an amino acid sequence comprising the amino acid sequence depicted in SEQ ID NO: 209; and (ii) a heavy chain polypeptide having an amino acid sequence comprising the amino acid sequence depicted in SEQ ID NO: 203.